How to buy ResMed (RMD) stocks

ResMed is a medical instruments & supplies business based in the US. ResMed shares (RMD) are listed on the NYSE and all prices are listed in US Dollars.

Its last market close was $237.27 – a decrease of 0.52% over the previous week.

Our top picks for where to buy ResMed stock

Buy ResMed stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

ResMed stock price (NYSE: RMD)

Use our graph to track the performance of RMD stocks over time.

ResMed stocks at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$237.27
52-week range	$162.60 - $259.93
50-day moving average more info button	$242.79
200-day moving average more info button	$219.25
Wall St. target price	$253.11
PE ratio more info button	30.4914
Dividend yield more info button	$1.97 (0.92%)
Earnings per share (TTM) more info button	$7.55

Is it a good time to buy ResMed stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

ResMed price performance over time

Historical closes compared with the close of $237.27 from 2024-12-20

1 week (2024-12-16)	-1.56%
1 month (2024-11-22)	-2.67%
3 months (2024-09-20)	-3.13%
6 months (2024-06-21)	15.27%

1 year (2023-12-22)	38.43%
2 years (2022-12-22)	15.62%
3 years (2021-12-23)	251.9743
5 years (2019-12-23)	58.99%

Is ResMed stock undervalued or overvalued?

Valuing ResMed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ResMed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ResMed's P/E ratio

ResMed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 30x. In other words, ResMed shares trade at around 30x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stock or simply that they're over-valued.

ResMed's PEG ratio

ResMed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7472. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ResMed's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

ResMed's EBITDA

ResMed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.6 billion.

The EBITDA is a measure of a ResMed's overall financial performance and is widely used to measure a its profitability.

ResMed financials

Revenue TTM	$4.8 billion
Operating margin TTM	31.63%
Gross profit TTM	$2.4 billion
Return on assets TTM	13.27%
Return on equity TTM	23.57%
Profit margin	23.15%
Book value	$35.39
Market Capitalization more info button	$33.8 billion

TTM: trailing 12 months

ResMed's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like ResMed.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

ResMed's total ESG risk score

Total ESG risk: 29.05

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and ResMed's overall score of 29.05 (as at 12/31/2018) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like ResMed is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

ResMed's environmental score

Environmental score: 7.42/100

ResMed's environmental score of 7.42 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ResMed is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

ResMed's social score

Social score: 14/100

ResMed's social score of 14 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ResMed is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

ResMed's governance score

Governance score: 12.64/100

ResMed's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that ResMed is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

ResMed's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. ResMed scored a 1 out of 5 for controversy – the highest score possible, reflecting that ResMed has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

ResMed Inc was last rated for ESG on: 2019-01-01.

Total ESG score	29.05
Total ESG percentile	50.28
Environmental score	7.42
Environmental score percentile	4
Social score	14
Social score percentile	4
Governance score	12.64
Governance score percentile	4
Level of controversy	1

ResMed stock dividends

Dividend payout ratio: 24.37% of net profits

Recently ResMed has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ResMed shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In ResMed's case, that would currently equate to about $1.97 per share.

While ResMed's payout ratio might seem low, this can signify that ResMed is investing more in its future growth.

ResMed's most recent dividend payout was on 11 December 2024. The latest dividend was paid out to all shareholders who bought their stocks by 6 November 2024 (the "ex-dividend date").

Have ResMed's stocks ever split?

ResMed's stocks were split on a 2:1 basis on 30 August 2010 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ResMed stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for ResMed stocks, which in turn could have impacted ResMed's stock price.

ResMed stock price volatility

Over the last 12 months, ResMed's stocks have ranged in value from as little as $162.6047 up to $259.928. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while ResMed's is 0.687. This would suggest that ResMed's stocks are less volatile than average (for this exchange).

ResMed overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of ResMed is owned by insiders or institutions?
Currently 0.773% of ResMed stocks are held by insiders and 61.3% by institutions. When does the fiscal year end for ResMed?
ResMed's fiscal year ends in June. Where is ResMed based?
ResMed's address is: 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123 What is ResMed's ISIN number?
ResMed's international securities identification number is: US7611521078 What is ResMed's CUSIP number?
ResMed's Committee on Uniform Securities Identification Procedures number is: 761152107

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.